



TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/761,922
		Filing Date	January 20, 2004
		First Named Inventor	REICH, CARY J.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Total Number of Pages in This Submission		Attorney Docket Number	017067-002910US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard PTO/SB/08A and /08B Form 0 Reference Copies
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP James M. Heslin Reg. No. 29,541
Signature	
Date	2/14/04


CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Edward Masinas		
Signature		Date	02-20-04

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 017067-002910US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 2-20-04



TOWNSEND and TOWNSEND and CREW LLP

By: Edward Masinas

Edward Masinas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

REICH, Cary J. et al.

Application No.: 10/761,922

Filed: January 20, 2004

For: HEMOACTIVE COMPOSITIONS
AND METHODS FOR THEIR
MANUFACTURE AND USE

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/330,315, filed June 10, 1999 (Attorney Docket No. 017067-002900US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



James M. Heslin
Reg. No. 29,541

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JMH:bjl
60139920 v1



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/761,922	
			Filing Date	January 20, 2004	
			First Named Inventor	REICH, CARY J.	
			Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	3	of	5	Attorney Docket Number	017067-002910US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	4,265,233	05/1981	Sugitachi et al.	
	AB	4,291,013	09/22/81	Wahlig et al.	
	AC	4,300,494	11/17/81	Graiff et al.	
	AD	4,347,234	08/31/82	Wahling et al.	
	AE	4,424,208	01/1984	Wallace et al.	
	AF	4,536,387	08/1985	Sakamoto et al.	
	AG	4,655,211	04/1987	Sakamoto et al.	
	AH	4,803,075	02/07/89	Wallace et al.	
	AI	4,891,359	01/1990	Saferstein et al.	
	AJ	4,925,677	05/15/90	Feijen	
	AK	4,946,870	08/07/90	Partain, II. et al.	
	AL	5,165,938	11/1992	Knighton	
	AM	5,178,883	01/1993	Knighton	
	AN	5,196,185	03/23/93	Silver et al.	
	AO	5,204,382	04/20/93	Wallace et al.	
	AP	5,292,362	03/1994	Bass et al.	
	AQ	5,352,715	10/04/94	Wallace et al.	
	AR	5,356,614	10/18/94	Sharma	
	AS	5,384,333	01/24/95	Davis et al.	
	AT	5,385,606	01/1995	Kowanko	
	AU	5,399,361	03/1995	Song et al.	
	AV	5,399,361	03/1995	Song et al.	
	AW	5,428,024	06/27/95	Chu et al.	
	AX	5,516,532	05/14/96	Atala et al.	
	AY	5,595,735	01/21/97	Saferstein et al.	
	AZ	5,648,506	07/15/97	Desai et al.	
	BA	5,672,336	09/30/97	Sharma	
	BB	6,066,325	05/2000	Wallace et al.	
	BC	6,110,484	08/2000	Sierra	
	BD	6,277,394	08/2001	Sierra	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1009B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/761,922	
			Filing Date	January 20, 2004	
			First Named Inventor	REICH, CARY J.	
			Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	4	of	5	Attorney Docket Number	017067-002910US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	BE	WO	96/06883		03/07/96	PCT		<input type="checkbox"/>
	BF	WO	96/10374		04/1996	PCT		<input type="checkbox"/>
	BG	WO	96/10428		04/1996	PCT		<input type="checkbox"/>
	BH	WO	96/39159		12/12/96	PCT		<input type="checkbox"/>
	BI	WO	98/08550		03/05/98	PCT		<input type="checkbox"/>
NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T ²
	BJ	Ansell et al., "Gelfoam and autologous clot embolization: Effect on coagulation" <i>Invest. Radiol.</i> (1978) 13:115-120.						
	BK	Barton et al., "Fibrin glue as a biologic vascular patch—a comparative study" (abstract posted at http://www.ncbi.nlm.nih.gov/ on 01/03/01 from) <i>J. Surg. Res.</i> (1986) 40(5):510-513.						
	BL	Bruck, S.D., Ed., "Controlled Drug Delivery", CRC Press, Boca Raton, FL (1983) (title page and table of contents).						
	BM	Cantor et al., "Gelfoam and thrombin in gastrointestinal bleeding: An experimental study" pp. 890-893.						
	BN	Cantor et al., "Gelfoam and thrombin in treatment of massive gastroduodenal hemorrhage: A preliminary report" <i>Am. J. Surg.</i> (1950) pp. 883-887.						
	BO	Cantor et al., "Gelfoam and thrombin in treatment of massive upper gastrointestinal hemorrhage" <i>Am. J. Surg.</i> (1951) pp. 230-235.						
	BP	Chuang et al. "Sheath needle for liver biopsy in high-risk patients" <i>Radiology</i> (1988) 166:261-262.						
	BQ	Collins et al., "Enemata of gelfoam-milk suspension combined with thrombin solution to control massive hemorrhage following anorectal surgery" <i>Am. J. Proctol.</i> (1951) 2:60-63.						
	BR	Edgerton et al., "Vascular hamartomas and hemangiomas: Classification and treatment" <i>Southern Med. J.</i> (1982) 75(12):1541-1547.						
	BS	Heller et al., "Release of norethindrone from poly(ortho esters)" <i>Polymer Engineering Scien.</i> (1981) 21(11):727-731.						
	BT	Hotz et al. "Collagen and fibrin as biologic binders for granular hydroxyapatite" (abstract posted at http://www.ncbi.nlm.nih.gov/ on 01/03/01 from) <i>Dtsch. Z. Mund. Kiefer Gesichtshir.</i> (1989) 13(4):296-300.						

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	10/761,922
Filing Date	January 20, 2004
First Named Inventor	REICH, CARY J.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	017067-002910US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	BU	Jeong et al., "Biodegradable block copolymers as injectable drug-delivery systems" <i>Nature</i> (1997) 388:860-862.						
	BV	Krill et al., "Topical thrombin and powdered Gelfoam: An efficient hemostatic treatment for surgery" <i>J. Tenn. Dent. Assoc.</i> (1986) 66(2):26-27.						
	BW	Langer et al., "Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: A review" <i>Rev. Macro. Chem. Phys.</i> (1983) C23(1):61-126.						
	BX	Leong et al., "Polyanhydrides for controlled release of bioactive agents" <i>Biomaterials</i> (1986) 7:364-371.						
	BY	Leong et al., "Polymeric controlled drug delivery" <i>Adv. Drug Delivery Review</i> (1987) 1:199-233..						
	BZ	Maok, "Hemostatic Agents" (1991) <i>Today's O.R. Nurse</i> , pp. 6-10.						
	CA	Masari et al., "Synthesis of polyurethanes and investigation of other hydrolytic stability" <i>Journal of Polymer Science, Polymer Symposium</i> (1979) 66:259-268.						
	CB	McClure et al., "Massive gastroduodenal hemorrhage: Treatment with powered Gelfoam and buffered thrombin solution" <i>Surg.</i> (1952) 32:630-637.						
	CC	Pitt et al., "Biodegradable drug delivery systems based on aliphatic polyesters: Application to contraceptives and narcotic antagonists" <i>Controlled Release of Bioactive Materials</i> , Baker, R., Ed., Academic Press, New York (1980) pp. 19-43.						
	CD	Riley et al., "Percutaneous liver biopsy with plugging of needle track: A safe method for use in patients with impaired coagulation" <i>Lancet</i> (August 25, 1984) pp. 436.						
	CE	Sidman et al., "Biodegradable, implantable sustained release systems based on glutamic acid copolymers" <i>Journal of Membrane Science</i> (1979) 7:227-291.						
	CF	Sugitachi et al. "Preoperative transcatheter arterial chemo-embolization for locally advanced breast cancer. Application for new thrombotic materials" <i>Japan J. Surg.</i> (1983) 13(5):456-458.						
	CG	Sugitachi et al., "A newly devised chemo-embolic agent, G.T. XIII-ADM." (English abstract posted at http://www.ncbi.nlm.nih.gov/ on 01/03/01 from) <i>Gan. To. Kagaku Ryoho.</i> (1985) 12(10) 1942-1943.						
	CH	Sugitachi et al., "Locoregional therapy in patients with malignant pleural effusion—two different types of BAC therapy" (English abstract posted at http://www.ncbi.nlm.nih.gov/ on 01/03/01 from) <i>Gan. To. Kagaku Ryoho.</i> (1992) 19(10):1640-1643.						

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FEB 25 2004

(use as many sheets as necessary)

Sheet

of	5
----	---

Application Number	10/761,922
--------------------	------------

<i>Filing Date</i>	January 20, 2004
--------------------	------------------

<i>First Named Inventor</i>	REICH, CARY J.
-----------------------------	----------------

Art Unit	Unassigned
----------	------------

Examiner Name	Unassigned
---------------	------------

Attorney Docket Number	017067-002910US
------------------------	-----------------

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.